Evidence map›Paper›PMID 35601804›Full record

ArticleTherapeutic advances in gastroenterology2022

Efficacy and safety of raltitrexed plus S-1

Yu-Wen Zhou, Jia-Ling Wang, Qing-Fang Li, Yuan-Lin He, Lin-Juan Li, Rui-Zhi Liu, Ye Chen, Shuang Zhang, Meng Qiu, Ji-Yan Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yu-Wen ZhouDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Jia-Ling WangDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Qing-Fang LiDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Yuan-Lin HeWest China School of Medicine, Sichuan University, Chengdu, China.
Lin-Juan LiDepartment of Abdominal Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Rui-Zhi LiuDepartment of Medicine and Life Science, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Ye ChenDepartment of Abdominal Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Shuang ZhangDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Meng QiuDepartment of Abdominal Oncology, Cancer Center, West China Hospital, Sichuan University, 37 Guoxue Xiang Street, Chengdu 610041, Sichuan Province, China.ORCID https://orcid.org/0000-0003-3722-6938
Ji-Yan LiuDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, 37 Guoxue Xiang Street, Chengdu 610041, Sichuan Province, China.
Sichuan University · CNChengdu University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Raltitrexed plus S-1 (RS) and regorafenib both showed considerable efficacy for metastatic colorectal cancer (mCRC) patients. This study aims to compare the effectiveness and safety of two different regimens in patients with refractory mCRC. Methods: This retrospective cohort study included mCRC patients who were treated with RS or regorafenib from February 2017 to June 2021. A propensity score matching (PSM) analysis was conducted to balance the baseline characteristics of all patients. Progression-free survival (PFS), overall survival (OS), tumor response, and safety of two regimens were evaluated. Results: A total of 187 patients were included in our study, with 107 patients in the RS group and 80 patients in the regorafenib group. After PSM, 78 pairs were recognized. Patients treated with RS had a semblable PFS compared to those treated with regorafenib before PSM (4.8 months Conclusion: Patients treated with RS demonstrated a longer OS than those treated with regorafenib and had manageable AEs, which could be recognized as a primary choice for refractory mCRC. Plain Language Summary:

Indexed as

colorectal cancerprognosisraltitrexedregorafenibS-1

Identifiers

PMID35601804
PMCPMC9121501
OpenAlexW4285233352

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.